84 related articles for article (PubMed ID: 3182113)
1. Pharmacokinetics and tissue distribution of ofloxacin in human subjects during a multiple dose regimen.
De Bernardis E; Bonaccorsi S; Carlino S; Picari M; Rizza V
Int J Clin Pharmacol Res; 1988; 8(4):239-45. PubMed ID: 3182113
[TBL] [Abstract][Full Text] [Related]
2. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of single rising doses of ofloxacin in healthy volunteers.
Marchbanks CR; Dudley MN; Flor S; Beals B
Pharmacotherapy; 1992; 12(1):45-9. PubMed ID: 1549538
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ofloxacin. An overview.
Flor S
Am J Med; 1989 Dec; 87(6C):24S-30S. PubMed ID: 2603892
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
Tsaganos T; Kouki P; Digenis P; Giamarellou H; Giamarellos-Bourboulis EJ; Kanellakopoulou K
Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825
[TBL] [Abstract][Full Text] [Related]
6. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
[TBL] [Abstract][Full Text] [Related]
7. Dose related pharmacokinetics of ofloxacin in healthy volunteers.
Immanuel C; Hemanthkumar AK; Gurumurthy P; Venkatesan P
Int J Tuberc Lung Dis; 2002 Nov; 6(11):1017-22. PubMed ID: 12475149
[TBL] [Abstract][Full Text] [Related]
8. Use of nonlinear, mixed-effects modeling for population analysis of ofloxacin: effects of age on oral drug pharmacokinetics.
Yuen GJ; Drusano GL; Brooks J; Flor S
Pharmacotherapy; 1992; 12(2):88-92. PubMed ID: 1570232
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, tissue residue and plasma protein binding of ofloxacin in goats.
Baruah H; Roy DC; Roy RK; Khonikor HN
J Vet Sci; 2004 Jun; 5(2):97-101. PubMed ID: 15192335
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Dalhoff A; Naber KG
Int J Antimicrob Agents; 2006 Jan; 27(1):7-14. PubMed ID: 16343856
[TBL] [Abstract][Full Text] [Related]
11. Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers.
Fillastre JP; Leroy A; Borsa-Lebas F; Etienne I; Gy C; Humbert G
Drugs Exp Clin Res; 1992; 18(11-12):487-92. PubMed ID: 1308475
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of ofloxacin in broiler chicken.
Kalaiselvi L; Sriranjani D; Ramesh S; Sriram P; Mathuram LN
J Vet Pharmacol Ther; 2006 Jun; 29(3):185-9. PubMed ID: 16669862
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of ocular tissue distribution of drug-related radioactivity after chronic oral administration of 14C-levofloxacin and 14C-chloroquine in pigmented rats.
Tanaka M; Takashina H; Tsutsumi S
J Pharm Pharmacol; 2004 Aug; 56(8):977-83. PubMed ID: 15285841
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats.
Albarellos GA; Ambros LA; Landoni MF
J Vet Pharmacol Ther; 2005 Aug; 28(4):363-9. PubMed ID: 16050816
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of levofloxacin in healthy Thai male volunteers.
Chulavatnatol S; Chindavijak B; Vibhagool A; Wananukul W; Sriapha C; Sirisangtragul C
J Med Assoc Thai; 1999 Nov; 82(11):1127-35. PubMed ID: 10659548
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of ofloxacin administered orally in elderly subjects with bronchial or urinary tract infections].
Bardin C; Clavier M; Darchis JP; Chauvin M; Veyssier P; Farinotti R
Therapie; 1992; 47(1):35-9. PubMed ID: 1523592
[TBL] [Abstract][Full Text] [Related]
18. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ofloxacin penetration into the skin after a single oral dose assessed by cutaneous microdialysis.
Bielecka-Grzela S; Klimowicz A
Pol J Pharmacol; 2003; 55(4):613-8. PubMed ID: 14581720
[TBL] [Abstract][Full Text] [Related]
20. Ofloxacin in human serum, urine, and tear film after topical application.
Borrmann L; Tang-Liu DD; Kann J; Nista J; Lin ET; Frank J
Cornea; 1992 May; 11(3):226-30. PubMed ID: 1587130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
